Elimova, E., Rha, S. Y., Shitara, K., Liu, T., Tabernero, J., Lee, K., Schenker, M., Tebbutt, N. C., Ajani, J. A., Salimin, N., Ku, G. Y., Kim, J. G., Diaz, I. A., Zhang, J., Pietrantonio, F., Bai, L., Sourd, S. L., Chen, Y., Grim, J. E., Shen, L. (2026). Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4042